NeoPharm reiterated at strong buy

JMP Securities analyst Charles C. Duncan reiterated NeoPharm, Inc. at strong buy and a $19 price target after the company's data monitoring committee recommended continuation of the phase 3 Precise trial to final efficacy analysis as expected. JMP believes the final efficacy analysis will show statistically significant survival improvement with CBtox treatment compared to Gliadel wafers. Shares of the Waukegan, Ill.-based biopharmaceutical company were down 28 cents, or 5.12%, at $5.19 on volume of 582,088 shares versus the three-month running average of 323,552 shares. (Nasdaq: NEOL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.